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Abstract
Melanoma patients carry a high risk of developing brain metastases, and improvements in survival are still
measured in weeks or months. Durable disease control within the brain is impeded by poor drug penetration
across the blood-brain barrier, as well as intrinsic and acquired drug resistance. Augmented mitochondrial
respiration is a key resistance mechanism in BRAF-mutant melanomas but, as we show in this study, this
dependence on mitochondrial respiration may also be exploited therapeutically. We first used high-throughput
pharmacogenomic profiling to identify potentially repurposable compounds against BRAF-mutant melanoma brain
metastases. One of the compounds identified was β-sitosterol, a well-tolerated and brain-penetrable phytosterol.
Here we show that β-sitosterol attenuates melanoma cell growth in vitro and also inhibits brain metastasis
formation in vivo. Functional analyses indicated that the therapeutic potential of β-sitosterol was linked to
mitochondrial interference. Mechanistically, β-sitosterol effectively reduced mitochondrial respiratory capacity,
mediated by an inhibition of mitochondrial complex I. The net result of this action was increased oxidative stress
that led to apoptosis. This effect was only seen in tumor cells, and not in normal cells. Large-scale analyses of
human melanoma brain metastases indicated a significant role of mitochondrial complex I compared to brain
metastases from other cancers. Finally, we observed completely abrogated BRAF inhibitor resistance when
vemurafenib was combined with either β-sitosterol or a functional knockdown of mitochondrial complex I. In
conclusion, based on its favorable tolerability, excellent brain bioavailability, and capacity to inhibit mitochondrial
respiration, β-sitosterol represents a promising adjuvant to BRAF inhibitor therapy in patients with, or at risk for,
melanoma brain metastases.
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Introduction
Melanoma incidence rates are increasing, and brain
metastases represent a leading cause of melanoma-asso-
ciated deaths [10, 14, 17, 48]. Even though phase II clin-
ical trials have shown promising therapeutic effects by
the use of BRAF inhibitors (BRAFi) +MEK inhibitors
(MEKi), resistance still develops [18, 32]. Also, in experi-
mental studies it has been shown that immunotherapy
combining anti-PD1 plus CTLA4 may have a thera-
peutic effect [59]. However, a major problem is the pre-
sence of the blood-brain barrier (BBB), which is intact
during early stages of brain metastasis development [51].
Although the presence of metastases can compromise
the structure and integrity of the BBB, it is still a signifi-
cant obstacle for efficient drug delivery [22, 31, 37, 66].
Moreover, cancer cells that have extravasated to the
brain parenchyma may find protection within the brain
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microenvironment, and be more prone to develop re-
sistance due to sub-therapeutic drug concentrations
[46, 52]. There are also significant concerns associated
with drug-related adverse effects, patient selection,
and costs versus benefits [56, 67]. Thus, there is a
prevailing need to find new therapeutic and preventive
approaches that offer improved and sustained responses
against brain metastases [3, 52].
Recently, it has been shown that molecular drivers of
cellular metabolic reprogramming events may be critical
in tumor development, metastasis formation and drug re-
sistance [1]. For instance, subsets of melanomas that show
primary resistance to targeted therapies seem to rely more
on mitochondrial respiration than glycolysis [45, 63].
Furthermore, when BRAF-mutant melanomas are treated
with vemurafenib (a BRAFi), the MITF-PGC1α axis is
up-regulated, which leads to increased mitochondrial res-
piration and scavenging of reactive oxygen species (ROS)
[24]. These intrinsic and acquired resistance mechanisms
provide obvious survival advantages, but the dependence
on mitochondrial respiration may also be exploited thera-
peutically [24, 45, 49, 63, 69].
The metabolic alterations that occur in melanoma brain
metastases are largely unknown, but cell lines derived
from metastatic melanomas and melanoma metastases
(non-brain) have shown elevated levels of mitochondrial
respiration when compared to primary melanomas [7, 26].
In the brain, metastatic breast cancer cells have been
shown to be less dependent on glucose, and instead utilize
mitochondrial respiration for energy production and
antioxidant defense [15, 16]. Moreover, metastatic breast
cancer cells have been shown to display neuron-like
characteristics in the brain microenvironment [39, 41].
Whether these changes reflect intrinsic or adaptive ca-
pabilities of tumor cells to thrive in the neural niche
remains to be determined. Nevertheless, to survive and
grow, extravasated cancer cells can adjust to the lower
glucose levels in the brain interstitium [16]. Notably, when
cancer cells are deprived of glucose they switch from gly-
colysis to mitochondrial respiration and become sensitive
to low doses of mitochondrial complex I (CI) inhibitors
that do not affect normal (non-cancerous) cells [40].
In this study (scientific flowchart outlined in Additional
file 1: Figure S1), using a well-established patient derived
metastatic xenograft model, we identified a melanoma
brain metastasis gene signature by RNA-sequencing
(RNA-seq). We then utilized the Connectivity Map drug
discovery tool (cMap; Broad Institute) to search for
putative therapeutic compounds with the potential to
invert the signature. The lead compounds identified were
then tested in predictive xenograft models of BRAF-mu-
tant melanoma brain metastases. Here, we show that
β-sitosterol, a well-tolerated and brain-penetrable phy-
tosterol, effectively prevented the emergence of brain
metastases leading to a significant survival benefit.
Mechanistically, we show that β-sitosterol targets mito-
chondrial CI that leads to an inhibition of mitochon-
drial respiration. We also show that β-sitosterol abrogates
potential resistance to BRAFi, inferring a clear therapeutic
rationale for using β-sitosterol as a therapeutic agent
towards melanoma metastases.
Materials and methods
Cell lines
The H1 cell line was generated from a human melanoma
brain metastasis and transduced with lentiviral vectors
expressing the genes for GFP and luciferase (H1_DL2) as
previously described [60], or shRNAs targeting NDUFA8
(H1_shNDUFA8; TAGAAGACGCACCGGCGGTGTTTA
GGGGAAGGTAAAGTTAATATTCATAGCTTTGCCTT
CCTCTAAACACCGTTTTTTGGCAAGCAAAAGACGG
CATACGAGATATGTACCAGTCAGTACCAGTTTCGC
CGTCTTCGT). The Melmet 1 and Melmet 5 melanoma
cell lines were developed from a skin and a lymph node
metastasis, respectively, and were kindly provided by Ø.
Fodstad (University of Oslo, Oslo, Norway). The A375 cell
line was purchased from the American Type Culture Col-
lection (ATCC). A human lung fibroblast cell line, SV-80,
was purchased from CLS Cell Lines Service GmbH. The
PC14-PE6 cell line was kindly provided by F. Winkler
(University Hospital Heidelberg & German Cancer
Research Center, Heidelberg, Germany), and a brain
seeking subline PC14_PE6_Br2 was generated in our
laboratory as described earlier [27]. The Melmet 1 and
Melmet 5 cell lines were transduced with a lentiviral
pGF1-CMV reporter vector that co-expresses copGFP
and firefly luciferase linked by the self-cleaving peptide
T2A (System Biosciences). The immortalized human
melanocytes-hTERT (cat. no. T0463) and astrocytes
(cat.no. T0281) were both purchased from Applied
Biological Materials (Richmond, BC, Canada). The primary
epidermal melanocytes HEMa (cat.no. PCS-200-013) were
purchased from ATCC. The H1, Melmet 1, Melmet 5 and
A375 cell lines have the BRAFV600E mutation. The trans-
duced cell lines were used in all experiments, authenticated
within the last six months using short tandem repeat (STR)
profiling, and maintained as previously described [57].
In vivo generation of samples for RNA sequencing
Eight weeks old female NOD.CB17-Prkdcscid/NcrCrl
mice were purchased from Charles River Laboratories
International. Anesthesia was induced with 3% and
maintained with 1.5% isofluorane in oxygen. We per-
formed intracardiac injections in seven mice (5 × 105
H1_DL2 cells suspended in 0.1 mL PBS) as previously
described [60]. Whole-body bioluminescence imaging
(BLI) was used to evaluate injection failure 10 min
post-injection and weekly over seven weeks to monitor
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metastasis formation (Additional file 2: Figure S2a) using
a Xenogen Ivis 100 Small Animal Molecular Imager
(Xenogen Corporation) as previously described [60]. At
seven weeks, we injected 150 mg/kg D-luciferin Firefly
(Gold Biotechnology), sacrificed the mice ten min later,
and performed ex vivo BLI to evaluate organ involve-
ment in detail. All animals invariably developed metasta-
ses in their brain, adrenals, ovaries, and femurs, and
these organs from five animals showing the highest
tumor burden on BLI, were dissociated using tailored
protocols based on the Liberase TM Research Grade en-
zyme reagent (Roche Applied Science; Additional file 3
Table S1). Sample yields of GFP positive tumor cells
were checked by fluorescence microscopy prior to cell
sorting (Additional file 2: Figure S2b) using the BD
Influx high-speed cell sorter (BD Biosciences). We aimed
for a minimum of 150,000 cells in each sample, and
picked the three tumor cell samples from each organ
with the most cells for subsequent RNA sequencing: 1)
brain (151,023, 150,835 and 154,797 cells); 2) adrenals
(151,968, 184,506 and 276,146 cells); 3) ovaries (159,736,
171,814 and 433,703 cells); and 4) femurs (120,530,
91,055 and 73,942 cells). These 12 samples (3 samples ×
4 organs) of metastatic melanoma cells were kept in 1%
FBS medium, pelleted by centrifugation, transported on
dry ice and stored in a − 80 °C freezer.
RNA isolation
Total cellular RNA was isolated from the cell pellets using
the TRIzol reagent (Life Technologies) and a modified
protocol that incorporates an additional extraction with
phenol/chloroform/isoamyl alcohol (25:24:1, pH 4.3). RNA
quantity and quality were assessed on a NanoDrop spec-
trophotometer (Thermo Scientific) and the Agilent 2100
Bioanalyzer (Agilent Technologies), respectively.
Library preparation for RNA sequencing
RNA sequencing (RNA-Seq) libraries were prepared
from 1.0 μg total RNA using the TruSeq RNA Sample
Preparation Kit (Illumina) according to the manufac-
turer’s protocol. Briefly, poly-adenylated mRNA was
purified from total RNA and ribosomal RNA removed
by two rounds of binding to magnetic poly-dT beads.
This was followed by RNA fragmentation by incubation
in the presence of divalent cations at 94 °C for 5 min.
Double-stranded cDNA was then generated by random-
primed first-strand synthesis with SuperScript II reverse
transcriptase and subsequent second strand synthesis
with RNase H and DNA Polymerase I. The cDNA was
then blunt-ended with T4 and Klenow DNA polyme-
rases to remove the 3′-overhangs and fill in 5′-over-
hangs, phosphorylated with T4 PNK, and then 3′-A
tailed by incubation with Klenow Fragment (3′→ 5′
exo–) and dATP. Illumina paired-end (PE) adapters were
then ligated, followed by purification with AMPure XP
beads. The library was then enriched by high-fidelity
PCR amplification (15 cycles) with Phusion DNA Poly-
merase (Finnzymes Oy) and adapter-specific primers.
The molar concentration of the libraries was determined
by measuring concentration with a Qubit fluorometer
(Invitrogen), determining the insert length with an
Agilent 2100 Bioanalyzer, and then qPCR-based quan-
tification (KAPA Library Quantification Kit).
RNA sequencing
Indexed libraries were pooled, loaded on TruSeq paired-
end flow cells, and paired-end sequencing (2 × 100 bp,
paired-end; 4 libraries/lane) was performed with an
Illumina HiSeq 2000 sequencing system (BGI@UC Davis
Joint Genome Center) using standard Illumina kitted
reagents (TruSeq SBS Kit v3-HS). Image processing,
base calling, quality scoring (Phred), and sample demul-
tiplexing were executed by HiSeq Control Software with
Real Time Analysis (HCS 1.5/RTA 1.13) and CASAVA
1.8 software (Illumina). The Tuxedo protocol (http://
compbio.mit.edu/cummeRbund) was followed using the
alternate protocol of quantification of reference anno-
tation only. We used Ensembl’s human genome build 19,
and supplied TopHat with a set of known transcripts
from Ensembl. The three BAM files from each individual
organ were merged using Picard 1.91 (http://broadinsti-
tute.github.io/picard), and these merged files were subs-
equently visualized using Integrative Genomics Viewer
2.3 (http://www.broadinstitute.org/igv). The cummeR-
bund package (http://compbio.mit.edu/cummeRbund)
and Partek Genomics Suite 6.12 (Partek Inc.) were used
to produce visualizations (Additional file 2: Figure S2c).
Gene expression analysis and brain metastasis gene
signature
We developed an integrated workflow of several inde-
pendent analyses to build a brain metastasis gene expres-
sion profile (Fig. 1b and Additional file 2: Figure S2d).
First, there were 134 genes differentially expressed in brain
metastases and metastases to any of the other organs; 122
genes were upregulated and 54 were downregulated in
brain (some genes appeared in multiple lists). Second, we
used Prediction Analysis for Microarrays (PAM; http://
statweb.stanford.edu/~tibs/PAM) to identify which of the
134 genes consistently distinguished brain metastases
from other organ metastases. We found ten upregulated
genes specific to brain metastases. Third, we validated
eight of these ten genes using a combination of other
computational analyses: A supervised rank product
analysis (RankProd; http://www.bioconductor.org/pack-
ages/release/bioc/html/RankProd.html) of brain metas-
tases compared with all the other organs pooled together
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(pfp < 0.01); a meta-analysis of rank product analyses
(RankProd) of brain metastases versus each of the other
organs (pfp < 0.01); and significance analysis of micro-
arrays (http://statweb.stanford.edu/~tibs/SAM) with a
q-value cutoff of 0.05. Fourth, we performed hierar-
chical clustering using J-Express 2012 (http://jexpress.
bioinfo.no/site) and identified 46 genes that clustered
together with the cross-validated eight-gene list; these
54 up-regulated genes were used to build a brain metas-
tasis gene signature. Fifth, to enable analysis with the
Connectivity Map (cMap) database, we appended the 54
most downregulated genes from the supervised rank
product analysis (RankProd) of brain metastases when
compared with all the other organs pooled together; all
of these 54 downregulated genes were also featured in
the 134-gene list of differentially expressed genes, as
described above. Thus, the 108-gene brain metastasis
signature was comprised of 54 upregulated and 54
downregulated genes (Additional file 2: Figure S2d).
Computational prediction of candidate compounds
We queried the cMap build 2 database (http://www.
broadinstitute.org/cmap) using our 108-gene signature
for candidate drugs. cMap is an initiative by the Broad
Institute of MIT and Harvard, where the effects of 1309
small molecules on a number of cultured human cells
were examined systematically, resulting in a collection of
more than 7000 expression profiles that can be freely
queried using their web interface. This resource can be
used to select for drugs that produce a disease-negating
gene signature. In this study, cMap was hypothesized to
predict drugs with the potential to induce opposite
expression profiles to those observed in our brain me-
tastasis gene signature (Additional file 2: Figure S2e).
Before cMap analysis, gene symbols were mapped to
HG-U133A probe IDs (microarray used in cMap). The
HG-U133A probe file (Platform GPL96) was down-
loaded and mapping was done with a code written in
our laboratory. Of the 54 upregulated genes, 37 genes
Fig. 1 Prediction of candidate compounds from inverse gene profiling. a Detailed mapping of organ involvement by ex vivo BLI of a representative
NOD.CB17-Prkdcscid/NcrCrl mouse seven weeks after intracardial injection of 5 × 105 H1_DL2 cells (n = 7). b Dendrogram of all replicates (n = 3 per
organ) based upon cluster analysis of gene expression profiles. Numbers 1, 2 and 3 indicate sample ID. c Top ten compounds from the Connectivity
Map (cMap) analysis with the potential to induce the opposite transcriptional response to the brain metastasis signature («anti-brain metastasis
signature»). Chemical abstracts service (CAS) registry numbers, reported dose tested, cMap score and molecular weight (MW) are provided. A cMap
score of − 1 indicates complete reversal of the signature (negative correlation)
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had at least one matching probe and 55 probes were
retrieved in total. Of the 54 downregulated genes, 29
genes had at least one matching probe, and 40 probes
were retrieved in total. Mappings were subsequently veri-
fied with the GeneAnnot (http://genecards.weizmann.ac.
il/geneannot/index.shtml) and GeneCards (http://www.
genecards.org) databases.
Candidate drugs
Nine drugs were purchased from Santa Cruz Biotechnol-
ogy, Inc.: Meticrane, tolazamide, β-sitosterol, memantine
hydrochloride (herein referred to as memantine), valproic
acid, letrozole, todralazine, thiostrepton, and levocabastine.
Niridazole was not available. For in vitro screening, all
compounds were dissolved in 100% dimethyl sulfoxide
(DMSO) to a stock concentration of 250mM. All stock
solutions were subsequently diluted in complete DMEM
to nine working solutions ranging from 0.2 to 1312.3 μM.
This dose spectrum covered well below and above the
reported dose levels for all drugs described in cMap.
PLX4720 (ChemieTek) was solubilized and diluted in a
similar manner to nine working solutions ranging from
0.01 to 1562.5 μM. Prior to in vitro testing, we pre-warmed
(37 °C) and sonicated all working solutions.
Proliferation assays
Cells from four BRAF mutated cell lines (H1_DL2,
Melmet 1, Melmet 5, A375) and three normal cell lines
(SV80; fibroblasts, hTERT melanocytes and human astro-
cytes) were quantified using a hemocytometer and seeded
into 96-well plates (5000 cells per well) in 100 μL
complete DMEM. After 24 h incubation, we added 100 μL
of the nine graded candidate drug dilutions, PLX4720, or
100 μL 0.1% or 1.0% DMSO in complete DMEM to each
well (n = 18 per cell line per drug per drug concentration).
Three days later, we added 20 μL of resazurin 0.1mg/mL
(Sigma-Aldrich Co.) per well and read the plates 4 h later
(Fig. 2a and Additional file 4: Figure S3a-f) using a
VICTOR X3 multilabel plate reader (PerkinElmer) with
Workout 2.5 data analysis software (560 nm excitation
and 590 nm emission). Wells with 200 μL complete
DMEM and no cells were used for background correc-
tion (n = 60). IC50 values were calculated (Fig. 2c, and
Additional file 4: Figure S3) using GraphPad Prism 6
for Mac OS X (GraphPad Software Inc.).
Fig. 2 In vitro drug screening. a Heatmap of three days H1_DL2 monolayer proliferation assays (left panel) and representative transmission (Trans)
and 4′,6-Diamidino-2-Phenylindole (DAPI) images (right panel). b Heatmap of ten days H1_DL2 tumorsphere assays (left panel) and representative
differential interference contrast (DIC) and green fluorescent protein (GFP) fluorescence microscopy images (right panel). a-b Right image panels
show examples of β-sitosterol 218.7 μM (top), β-sitosterol 2.7 μM (middle) and control (bottom). c Half maximal inhibitory concentration (IC50)
values for the three most potent compounds across different cell lines and assays. (a–c) Mean; n = 6 per cell line per drug per drug concentration.
See Additional file 4: Figure S3a–c for more details on this experiment
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Cells were fixed by adding 50 μL 8% paraformaldehyde
(PFA) per well for 24 h after which time the liquid contents
of all wells were replaced with 50 μL PBS. Differential inter-
ference contrast (DIC) and 4′,6-diamidino-2-phenylindole
(DAPI) image stacks were acquired (Fig. 2a) with 10× mag-
nification using a Nikon Eclipse TE2000 inverted micro-
scope (Nikon Instruments Inc.).
Tumorsphere assay
A standardized 3D tumor spheroid growth assay was
carried out as reported previously [58]. Briefly, 100 μL of
the graded drug dilutions and DMSO controls were
added to 96-well plates with 4000 cells in soft agar per
well (n = 6 per cell line per drug concentration). After a
ten-day incubation period, a resazurin assay was per-
formed, and cells were fixed as described above. DIC
and GFP z-stack images were acquired with 10× magni-
fication using a BD Pathway 855 High-Content Imager
(Becton, Dickinson and Company).
Tumor cell injections, quantification of tumor cell load in
the brain and multimodal imaging of metastasis
formation
Six to eight weeks old female NOD/SCID mice were
purchased from the University of Bergen animal facility.
Anesthesia was induced with 3% and maintained with
1.5% isoflurane in oxygen. Mice were monitored daily
and sacrificed upon signs of illness. Intracardiac injec-
tions were performed using ultrasound-guidance (5 × 105
cells per 0.1 mL PBS per mouse) as reported previously
[58]. H1_DL2 cells were pre-labeled with superparamag-
netic iron oxide nanoparticles and MRI was carried out
24 h after injections [57]; T2*-weighted images for auto-
mated quantification of tumor cell load in the mouse
brains and T2-weighted images to assess the presence of
focal brain lesions. MRI equipment and sequence details
have previously been described [58]. For T2*-weighted
quantification we developed a cell-line specific training
set for the integrated neural network analysis. Only mice
with comparable tumor cell load in their brains and
without ischemic lesions were included in further stud-
ies. We omitted five mice in the candidate drug study
and six mice in the β-sitosterol study, based on an
uneven tumor load to the brain.
We performed brain MRI to evaluate the brain me-
tastatic burden with T2-weighted sequences and pre
−/post-contrast T1-weighted sequences as previously de-
scribed [58]. Images were obtained at pre-defined week
numbers (Figs. 3a, b and 4a, b). The number of tumors,
contrast enhancement and volume (4/3 × π × r3) were
assessed using OsiriX 5.8.1 32-bit (Pixmeo SARL).
In parallel with the MRI, we did BLI to evaluate brain
metastatic burden. Mice were imaged 10 min after i.p.
injection of 150 mg/kg D-luciferin Firefly (Gold
Biotechnology). To reduce distress, they were not depi-
lated. Images were acquired using an Optix MX3 Small
Animal Molecular Imager (ART Inc.) and analyzed with
Optix OptiView 3.02 (ART Inc.). Total photon counts
(ventral + dorsal) were registered from identically sized
regions of interest (ROIs) placed over the head.
In vivo treatment protocols
In the drug screening study on H1_DL2 brain metasta-
ses, treatment started one week post-injection and
stopped at the end of week seven (Fig. 3a and Additional
file 5: Figure S4). Test groups received 0.2 mL i.p. injec-
tions of 40 mg/kg thiostrepton every second day (n = 5),
10 mg/kg memantine daily (n = 5), 5 mg/kg β-sitosterol
daily (n = 4), or 0.5% DMSO (n = 5) daily. Stock solutions
of the respective drugs, as described above, were diluted
with saline solution, pre-warmed (37 °C) and sonicated
prior to i.p. injections (the partly miscible thiostrepton
solution was homogenized before administration). Fresh so-
lutions were made every second week and stored at 4 °C.
In the validation study with β-sitosterol treatment on
H1_DL2 cells and PC14_PE6_Br2 brain metastases,
treatment started one week prior to intracardiac injections
and was continued until sacrifice for the vehicle groups
(n = 10) and for ten weeks for the β-sitosterol groups
(n = 9). Test groups received daily i.p. injections of 0.1
mL olive oil or 5 mg/kg β-sitosterol in 0.1 mL olive oil.
β-sitosterol was mixed with olive oil (Santa Cruz Bio-
technology Inc) and solubilized over 4 h with a heated
magnetic stirrer (50 °C). Fresh solutions were made
every second week and stored at room temperature.
In the subcutaneous tumor model, we used the Melmet
5 melanoma cell line. We injected 1 × 106 cells in 0.1 mL
PBS in the cervical skin fold of 32 mice. After two weeks,
when the average tumor volume was approximately
30 mm3, the mice were randomized to daily i.p. injections
of 0.1 mL vehicle (olive oil), 20mg/kg β-sitosterol in olive
oil, 25mg/kg PLX4720 in 0.05% DMSO, or a combination
of the two latter (n = 8 in each group). Caliper measure-
ments were carried out every sixth day to evaluate tumor
growth. Tumor volume was calculated using the formula
(width2 × length)/2.
Functional classification of the brain metastasis gene
signature
We performed a functional classification of human bio-
logical processes and signaling pathways associated with
the 108-gene signature using the Protein Analysis Through
Evolutionary Relationships (PANTHER) classification
system (http://www.pantherdb.org/).
Protein interactions of β-sitosterol
We examined known and predicted protein interactions
of β-sitosterol using the Search Tool for Interactions of
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Chemicals (STITCH 4.0; http://www.stitch.embl.de). We
applied a high confidence level cut-off (0.700) and a
maximal number of interactions (n = 50). We next in-
vestigated with which cellular processes these protein
targets were associated using the Human Experimental/
Functional Mapper (HEFalMp).
Protein phosphorylation assay
For the determination of the relative levels of protein
phosphorylation of 43 kinases and 2 related total
proteins (HSP60 and β-Catenin), we used the Human
Phospho-Kinase Array (R&D Systems, Inc.) as specified
by the manufacturer. H1_DL2 cells were treated with
vehicle (0.05% DMSO) or β-sitosterol (50 μM) for 24 h.
Linkage analyses to mitochondrial metabolism
We obtained the mitochondrial metabolism genes
from the Gene Ontology (GO) database using AmiGO
(http://amigo.geneontology.org/amigo) and the search
term «oxidative phosphorylation» (filter: Homo sapiens).
This resulted in 121 unique gene symbols among a total
of 209 gene-term associations. β-sitosterol targets were
extracted from ChEMBL (Chemical Database of the
European Molecular Biology Laboratory; https://www.ebi.
ac.uk/chembl): 16 targets reported in humans. CHEM-
BL_IDs were converted to gene symbols with UnitProtKB
(Universal Protein Resource Knowledgebase; http://www.
uniprot.org). Network generation and visualization were
implemented in Cytoscape 3.3.0 (http://www.cytoscape.
org). Interactions between query and mitochondrial me-
tabolism gene sets were extracted with ANAT (Advanced
Network Analysis Tool; http://www.cs.tau.ac.il/~bnet/
ANAT). β-sitosterol targets and signature genes were
defined as network anchors, and the oxidative phospho-
rylation genes as network terminals. Anchored network
analysis was applied with focus on: human interactions,
Fig. 3 In vivo drug screening. a Experimental overview: Intracardiac injections of 5 × 105 H1_DL2 cells in NOD/SCID mice were followed by MRI-
based quantification of nanoparticle-labeled melanoma cells in the mouse brains after 24 h for group homogenization (Additional file 5: Figure
S4a). Treatment started after one week, and test groups received 0.2 mL i.p. injections of 40 mg/kg thiostrepton every second day (n = 5), 10 mg/
kg memantine daily (n = 5), 5 mg/kg β-sitosterol daily (n = 4) or vehicle (0.5% DMSO; n = 5). See Additional file 5: Figure S4 for more details. b
Development of brain metastases visualized by MRI (T1-weighted images with contrast) and BLI at five, six and seven weeks. Scale bar MRIs, 0.25
cm. c Number of brain metastases at T1-weighted MRI with contrast (Student’s t-test). d Kaplan-Meier survival plot (Mantel-Cox log-rank test).
There was no significant difference between vehicle- and memantine-treated mice. * P < 0.05; ** P < 0.01. All values are given as the mean ± s.e.m
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protein-protein and protein-DNA interactions and default
search parameters. Interaction directionality from anchors
to terminals was specified.
Extracellular flux analysis
Extracellular flux analysis with concurrent detection
of oxygen (mitochondrial respiration) and pH (lactate
production indicating glycolysis) was employed. The
measurements were performed in 96-well H1_DL2
and HEMa cell cultures using the Seahorse XF96
Analyzer system (Seahorse Bioscience), according to
manufacturer’s protocol. The assay conditions were
optimized with regard to cell number and concentra-
tions of carbonyl cyanide 3-chlorophenylhydrazone
(CCCP) or carbonyl cyanide-4 (trifluoromethoxy) phe-
nylhydrazone (FCCP) and oligomycin. Cells were seeded
in quadruplicate wells (2 × 104 cells per well), and exposed
to 50 μM β-sitosterol for 24 h before the analysis. Control
cells received 0.05% DMSO. Following this treatment, the
growth medium was replaced with assay medium con-
sisting of phenol-free DMEM supplemented with 2mM
L-glutamine and 2mM sodium pyruvate. 10mM glucose
was added to the medium for measurement of mitochon-
drial respiration. The assay medium was adjusted to a pH
of 7.4. The cells were incubated at 37 °C in a CO2-free
incubator (Seahorse XF Prep station) for 1 h before they
were transferred to the analyzer. To investigate mitochon-
drial respiratory function, assessment of the initial oxygen
consumption rate (OCR), indicating the basal rate, was
followed by sequential additions of several modulators: 1)
the ATP synthase inhibitor oligomycin (3 μM for H1_DL2
and 2 μM for HEMa cells) was used to measure phospho-
rylation independent respiration (Leak); 2) the uncoupler
CCCP or FCCP (1.5 or 2 μM for H1_DL2 and HEMa cells,
Fig. 4 In vivo validation of β-sitosterol pre-treatment. a Experimental overview: Treatment started one week prior to intracardiac injections of 5 × 105
H1_DL2 cells in NOD/SCID mice. Quantification of tumor cell exposure in the mouse brains was carried out 24 h after injections for group
homogenization (Additional file 6: Figure S5a). Test groups received daily i.p. injections of 0.1 mL vehicle (olive oil; n = 10) or β-sitosterol diluted in olive
oil (5 mg/kg; n = 9). Vehicle treatment was continued until euthanization and β-sitosterol was given for ten weeks. See Additional file 6: Figure S5 for
more details on this experiment. b Development of brain metastases assessed by MRI at four, six, seven and eight weeks. Scale bar MRIs (T1-weighted
images with contrast), = 0.25 cm. c Number of brain metastases assessed by T1-weighted MRI with contrast (Student’s t-test). The mean number of
brain metastases in the vehicle group decreased slightly from seven to eight weeks as four mice with the greatest number of brain metastases were
sacrificed between these observation points. d Brain BLI at seven and eight weeks (total photon count = dorsal + ventral region of interest
(ROI); Student’s t-test). e Kaplan-Meier survival plot (Mantel-Cox log-rank test). The experiment was terminated at 100 days, and three mice
in the β-sitosterol group were still alive and healthy. * P < 0.05; ** P < 0.01; **** P < 0.0001. All values are given as the mean ± s.e.m
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respectively) to measure the capacity of the electron trans-
port system (respiratory capacity); 3) the Complex I (CI)
inhibitor rotenone (1 μM) to determine CI independent
respiration; and 4) the CIII inhibitor antimycin A (1 μM)
to assess residual background OCR not related to mito-
chondrial respiration; this was subtracted as background
from the other measurements in the statistical analysis.
To analyze the glycolytic function, the extracellular acidifi-
cation rate (ECAR) was measured after sequential addi-
tions of glucose (10mM) to determine basal glycolysis and
oligomycin (3 μM) to obtain glycolytic capacity. CCCP
(1.5 μM) was injected to address the possible influence of
uncoupling, and 2-deoxyglucose (2-DG; 100mM) was
used to obtain the non-glycolytic background. In statistical
analysis, the residual ECAR was subtracted as background
from the other measurements. All experiments were
performed three times.
High-resolution respirometry
Oxygen consumption was analyzed using the Oxygraph
O2K instrument and DatLab software (Oroboros Instru-
ments). The H1_DL2 cells were harvested and washed in
PBS before they were suspended in the assay medium (20
mMK-hepes, 83mM KCl, 4mM KH2PO4, 1mM EGTA
and 1mM MgCl2) and transferred to the assay chamber
(37 °C) at 1.25 × 106 cells per 2mL assay medium. Digitonin
(8.1 μM) was added to permabilize the cell membrane. The
combined CI + CII-driven respiration was obtained in the
presence of malate (2mM), pyruvate (1mM), succinate (10
mM), and FCCP (titrated to 0.18 μM). Following injection
of β-sitosterol (50 μM) or DMSO (0.05%) and assessment of
the resulting OCRs, rotenone (0.5 μM) was injected to de-
termine if the effect was linked to CI and/or CII. Antimycin
A (2.3 μM) was added to provide the non-mitochondrial
background activity, which was subtracted during data
analysis. This experiment was performed three times.
Measurement of reactive oxygen species and apoptosis
assay
H1_DL2 cells were treated with 0.05% DMSO or 50 μM
β-sitosterol for 24 h, and apoptosis was detected and
quantified using the disodium salt of 3, 4, 5, 6,-tetra-
chloro-2′, 4′, 5′, 7′-tetraiodofluorescein (TCTF) as pre-
viously described (n = 3) [34]. The cellular content of
reactive oxygen species (ROS) was measured using the
CM-H2DCFDA probe according to the manufacturer’s
instructions (Life Technologies). Briefly, naïve H1 cells
were treated with 0.05% DMSO or 50 μM β-sitosterol
for 2 h before exposure to 5 μM CM-H2DCFDA for 15
min (two experiments with triplicate measurements). Data
were analyzed using a BD Accuri C6 flow cytometer (BD
Biosciences).
Western blot
Protein extraction and western blotting was carried out
as described previously [58]. Antibodies were diluted in
blocking buffer and the following antibodies were used:
Caspase-3 (1:500) and PGC1α (1:500) (Cell Signaling
Technology); and NDUFA8 (ab74126; 1:500), GAPDH
(1:20,000) and β-actin (1:20,000) (Abcam).
MitoTracker red fluorescence
MitoTracker Red (Invitrogen) mean fluorescence inten-
sity was measured in H1 cells treated with DMSO
(0.05%) or PLX4720 (1.5 μM) for 72 h (n = 3). Data were
analyzed using a BD Accuri C6 flow cytometer (BD
Biosciences).
Colony formation assay
5 × 103 H1 cells were cultured in 6-well plates and treated
with DMSO (0.05%), PLX4720 (1.5 μM), β-sitosterol
(50 μM), or a combination of the latter two for one
(controls) or three weeks (treatment groups) (n = 3).
The same protocol was used for H1_shNDUFA8 cells,
but these were not treated with β-sitosterol.
Immunohistochemistry of human brain metastases
We stained 197 formalin-fixed and paraffin-embedded hu-
man brain metastases using NDUFB8 (ab110242; Abcam).
Samples were derived from melanoma (n = 78), non-small
cell lung cancer (n = 52), breast cancer (n = 25), renal cell
cancer (n = 9), colon cancer (n = 9), small cell lung cancer
(n = 7), carcinomas not otherwise specified (n = 9) and
other rare cases like ovarian and esophageal cancer
(n = 8). All staining procedures were performed using
an automated immunostainer (Leica Bond III) and ana-
lyzed by ≥ two observers using a semi-quantitative score
(H-Score) ranging from 0 to 300. H-Score is defined by
the staining intensity (1 = weak, 2 =moderate, 3 = strong)
multiplied with the frequency of positive cells (%).
Statistics
Statistical analyses were conducted with SPSS 21 for
Mac (SPSS Inc.) and Prism 7 for Mac, Version 7.0b (La
Jolla, CA, USA). An independent samples Student’s
t-test was used to compare two normally distributed
groups. The Kruskal-Wallis test was used to analyze
nonparametric data and Dunn’s or Sidak’s test was used
to correct for multiple testing. Levene’s test was used to
assess the variance. Kaplan-Meier survival analysis and
Mantel-Cox log-rank test were used to assess survival
differences between groups. Values are presented as
means ± standard error of the mean (s.e.m.) unless
otherwise specified. A two-tailed P ≤ 0.05 was considered
significant.
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Study approval
We obtained written informed consent before human
tumor material was collected. The Regional Ethical
Committee and the Norwegian Directorate of Health
approved the collection and storage of human tissue.
The Institutional Animal Care and Use Committee at the
University of California Davis and at the University of
Bergen approved the mouse experiments. At both institu-
tions, mice were maintained in animal facilities certified
by the Association for Assessment and Accreditation of
Laboratory Animal Care International. The local ethical
committee at the University Cancer Center Frankfurt
approved the immunohistochemical analyses of human
brain metastases.
Results
Predicting therapeutic compounds using inverse gene
expression profiling
Using a highly characterized metastatic BRAF-mutant
human melanoma xenograft model [57], we isolated and
sorted tumor cells from brain, bone, adrenals and ovaries
by flow cytometry (Fig. 1a, Additional file 2: Figure S2a,
b). By comparing RNA-seq data from the different metas-
tases, we identified a 108-gene brain metastasis signature
using a comparative workflow of independent analyses of
gene expression profiles from brain versus the other organ
metastases (Fig. 1b, and Additional file 2: Figure S2c, d).
The signature consisted of 54 upregulated and 54 down-
regulated genes (Additional file 2: Figure S2d). To identify
therapeutic compounds with the potential to revert the
gene signature, we queried cMap with the 108-gene brain
metastasis signature. cMap revealed 1313 expression pro-
files, with a cMap score < 0, which represent compounds
with the potential to induce the opposite transcriptional
response when compared with the signature (Additional
file 2: Figure S2e). For further studies, we focused
on the top 10 candidate compounds (all with cMap
scores < − 0.90) as shown in Fig. 1c.
In vitro and in vivo drug screening reveals β-sitosterol as
a potential therapeutic agent
The therapeutic efficacy of the compounds was assessed
on four metastatic melanoma cell lines using mono-
layer viability and tumorsphere assays (Fig. 2a-c and
Additional file 4: Figure S3). IC50 values were generally
lower in tumorspheres than in monolayers. The most
potent compounds for reducing viability were thiostrep-
ton, memantine, and β-sitosterol (Fig. 2a, b). The IC50
values for normal human fibroblasts and astrocytes were
128.3 μM and 1200.5 μM respectively, whereas normal hu-
man melanocytes were not sensitive to β-sitosterol within
the dose range studied (Additional file 4: Figure S3).
We next assessed the therapeutic efficacy of thios-
trepton, memantine, and β-sitosterol using a highly stan-
dardized human-to-mouse brain metastasis model [57]
(Fig. 3a). Quantitative analysis of baseline H1_DL2
melanoma cells (i.e. accumulation of tumor cells within
the brain 24 h after injection) showed no significant
differences between the treatment and vehicle (control)
groups (Additional file 5: Figure S4a). Drug treatment
was commenced one week after tumor cell injections.
High-resolution magnetic resonance imaging (MRI) over
the next 5–10 weeks revealed a significant reduction in
the number and volume of brain metastases in the
β-sitosterol-treated mice when compared with vehicle-
treated mice (Fig. 3b, c and Additional file 5: Figure S4b).
There were no differences in brain metastasis frequency
or size between the vehicle and the thiostrepton or
memantine groups (Student’s t-test, P ≥ 0.05 for all
comparisons). BLI intensity was significantly lower for
the β-sitosterol group when compared to the vehicle
group at all time points, with the exception of brain
BLI intensity at five weeks (Student’s t-test, P ≥ 0.05;
Additional file 5: Figure S4c). Importantly, β-sitosterol-
treated mice survived significantly longer than vehicle-
treated mice, whereas thiostrepton-treated mice had a
significantly shorter lifespan. Also, memantine treatment
did not affect survival (Fig. 3d).
β-Sitosterol pre-treatment inhibits the formation of brain
metastasis and increases animal survival
To further validate the β-sitosterol treatment effect, we
performed a new and more extensive in vivo study where
β-sitosterol treatment started 1 week before tumor cell in-
jection (Fig. 4a). MRI-based quantification of baseline
H1_DL2 melanoma cells in mouse brains again showed
an equal tumor cell exposure in the β-sitosterol and
vehicle groups (Additional file 6: Figure S5a). Vehicle-
treated mice progressively lost weight from four weeks
and onwards, whereas β-sitosterol-treated mice main-
tained a stable body weight (Additional file 6: Figure S5b).
There were significantly fewer and smaller brain metasta-
ses in the β-sitosterol group than in the vehicle group
(Fig. 4b, c and Additional file 6: Figure S5c). Brain BLI
intensity was significantly lower in the β-sitosterol treat-
ment group compared to the vehicle group at comparable
time points (Fig. 4d). β-sitosterol treatment provided a
significant survival benefit when compared with vehicle
treatment (Fig. 4e). When the study was terminated at
100 days, three out of nine mice treated with β-sitosterol
were healthy and tumor-free as evaluated by brain MRI
and histology. To confirm that the effects observed were
not associated with the model used, we performed the
same study using another highly aggressive brain tropic
cell line (PC14_PE6_Br2). Also here, a significant
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reduction in brain metastatic burden was seen leading to a
significant improved survival (Additional file 7: Figure S6).
β-Sitosterol targets mitochondrial respiration through
complex I inhibition
To obtain mechanistic insight into the therapeutic action
of β-sitosterol, we first examined the biological processes
and signaling pathways associated with our brain metas-
tasis signature. Functional classification of the signature
genes showed an association with human metabolic pro-
cesses and a number of cancer-related signaling pathways
(Additional file 8: Figure S7a, b). We next examined
known and predicted protein interactions of β-sitosterol
and found direct interactions with 12 proteins within
two distinct clusters related to apoptosis and choles-
terol homeostasis (Additional file 8: Figure S7c). These
12 proteins acted in conjunction and were significantly
associated with several biological processes, particularly
metabolism and cell division (Additional file 8: Figure S7d).
In order to explore whether specific signal transduction
pathways were affected through the treatment with β-si-
tosterol, we performed a phosphorylation screen in
vitro, and found reduced phosphorylation levels of a
large number of oncogenic kinases following β-sitosterol
treatment (Additional file 9: Figure S8). These data
connected major regulators of cell homeostasis to the
therapeutic potential of β-sitosterol and suggested that
β-sitosterol may interfere with basic cellular functions
such as energy metabolism and apoptosis.
Previous studies have shown that metastatic cells
adapt their energy production in order to thrive in the
brain microenvironment by increasing their mitochon-
drial respiration. This process has been shown to be a key
mediator of resistance to BRAFi [15, 16, 24, 63]. We
therefore investigated, by bioinformatics analyses, protein-
protein and protein-DNA interactions between the 121
Gene Ontology-annotated genes implicated in oxidative
phosphorylation and (a) our brain metastasis signature or
(b) known β-sitosterol targets. These analyses revealed
large interaction networks with centrally located signature
genes (Additional file 10: Figure S9) and β-sitosterol tar-
gets (Additional file 11: Figure S10). These data indicate
that the therapeutic effect of β-sitosterol is linked to mito-
chondrial interference. Thus, we measured mitochondrial
respiration and glycolysis by extracellular flux analysis in
H1_DL2 melanoma cells following β-sitosterol treatment.
As shown in Fig. 5a, β-sitosterol strongly reduces basal
mitochondrial respiration and respiratory capacity. The
extracellular flux analysis further shows that inhibition
of ATP synthase (with oligomycin) is similar in vehicle-
and β-sitosterol-treated cells (Fig. 5a), indicating that
β-sitosterol does not disrupt the integrity of the mito-
chondrial inner membrane. Inhibition of respiratory CI
revealed that most of the respiratory activity is linked
to this complex (Fig. 5a) and importantly, suggested
that CI was a likely β-sitosterol target. Basal glycolysis
and glycolytic capacity were, however, unaffected by
β-sitosterol (Fig. 5b). Interestingly, melanoma cells
showed minimal glycolytic reserve (glycolytic capacity
minus basal glycolysis) if mitochondrial ATP produc-
tion should cease (Fig. 5b). Thus, the cells could be par-
ticularly sensitive to inhibitors of mitochondrial
respiration such as β-sitosterol. For comparison, we also
measured the respiratory capacity of normal melanocytes
following β-sitosterol treatment. Compared to the tumor
cells, no changes in respiratory capacity was observed
(Additional file 12: Figure S11).
To determine if the inhibitory effect of β-sitosterol on
mitochondrial respiration was directly linked to the
activity of CI or CII, we analyzed oxygen consumption
rates in permeabilized cells by high-resolution respirome-
try. The CI + CII-driven respiratory activity was inhibited
immediately following β-sitosterol exposure (Fig. 5c).
Addition of the CI inhibitor, rotenone, did not provide
further inhibition, and the remaining CII-driven rate
was similar in the presence of β-sitosterol or rotenone
(Fig. 5c). In summary, β-sitosterol inhibits mitochondrial
respiration in tumor cells by acting as a CI inhibitor. Such
an inhibition was not seen in normal melanocytes.
β-Sitosterol increases oxidative stress and induces
apoptosis
Beyond their function in ATP synthesis, mitochondria are
major producers of ROS. CI respiratory capacity is of par-
ticular importance in this respect, −and inhibition of its
activity often results in increased ROS production [36].
Consistent with previous studies [4, 50], we observed a
significant increase in cellular ROS content following
β-sitosterol treatment (Fig. 6a). Interestingly, recent obser-
vations have shown that oxidative stress inhibits meta-
static melanoma cells in the blood and visceral organs in
vivo [42]. Since increased ROS levels have been linked to
apoptosis induction, we next performed apoptosis
analyses. As shown in Fig. 6b, a significant induction of
apoptosis was observed following β-sitosterol treat-
ment. This is in line with previous studies showing that
β-sitosterol can induce both mitochondrial- and death
receptor-mediated apoptosis in cancer cells [4, 8, 23,
50, 64, 65, 70]. Additionally, immunoblots for apoptotic
markers (Fig. 6c) confirmed our protein interaction
analysis (Additional file 8: Figure S7c). In summary,
respiratory capacity is inhibited following β-sitosterol
treatment which leads to an induction of apoptosis. In
this context, it should also be emphasized that apop-
tosis is a hallmark of MAPK-targeted therapies as well
as mitochondrial inhibitors, including known inhibitors
of CI-mediated respiration [24, 36, 68].
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β-Sitosterol abrogates potential resistance to BRAF
inhibition
Consistent with our previous observations that β-sitosterol
inhibits mitochondrial respiration (Fig. 5a) and increases
oxidative stress (Fig. 6a), we found a compensatory increase
in PGC1α expression with increasing concentrations
of β-sitosterol (Fig. 7a). The MITF-PGC1α axis is a
master regulator of mitochondrial function in melano-
mas [24, 63]. PGC1α promotes mitochondrial respi-
ration and protects against oxidative stress. A subset
of melanomas overexpresses PGC1α, and treatment of
BRAF-mutant melanomas with the BRAFi PLX4720 (a
vemurafenib analogue) has been shown to upregulate
PGC1α [24, 63]. In agreement with these data, we
Fig. 5 (See legend on next page.)
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found that PLX4720 induced MitoTracker Red fluo-
rescence, a measure of mitochondrial activity and mass
(Fig. 7b). Importantly, these intrinsic and acquired survival
advantages render melanoma cells resistant to BRAFi,
and combined approaches that exploit the resultant
dependence on mitochondrial respiration are highly
sought [24, 45, 49, 63, 69].
We therefore investigated the possible therapeutic
benefits of combining BRAFi and mitochondrial CI
inhibitors in colony formation assays. Both PLX4720
and β-sitosterol were effective as monotherapies, but
regrowth of resistant clones appeared after long-term
incubation (Fig. 7c). Combination treatment with PLX4720
and β-sitosterol, however, completely inhibited cell growth
(Fig. 7c). To further substantiate the therapeutic potential
of targeting mitochondrial CI (Fig. 5a, c), we constructed a
stable NDUFA8 knockdown in the H1 melanoma cell line
(H1_shNDUFA8) (Fig. 7d). NDUFA8 is an accessory
subunit of mitochondrial CI, in which knockdown results
in failure of a functional complex and severe respiratory
deficiency [55]. Long-term colony formation assays
with PLX4720 alone or H1_shNDUFA8 alone displayed
attenuated growth, whereas the combination totally
eliminated cell growth (Fig. 7e). Next, we examined
whether or not the combined effect was cell line spe-
cific. We performed monolayer viability assays in three
other melanoma cell lines. Combination treatment with
β-sitosterol and PLX4720 substantially reduced the IC50
values for all cell lines (Fig. 7f ). As BRAFis in general
have limited penetrability through an intact BBB [37] and
the BBB is commonly not degraded in animal models until
late in metastatic development [60], we carried out a proof
of concept study in a subcutaneous Melmet 5 melanoma
model. Both PLX4720 and β-sitosterol were effective as
monotherapies, but combination treatment significantly
reduced tumor growth (Fig. 7g).
To evaluate CI activity and the potential clinical rele-
vance of our findings, we performed immunohistoche-
mical staining of NDUFB8 (accessory subunit of CI) in
197 human brain metastases from various cancers.
(See figure on previous page.)
Fig. 5 β-sitosterol reduces mitochondrial respiration through complex I inhibition. a-b Oxygen consumption rate (OCR) and extracellular
acidification rate (ECAR) were measured to assess rates of mitochondrial respiration and glycolysis, respectively, in H1_DL2 cells treated with
50 μM β-sitosterol or 0.05% DMSO for 24 h (both: n = 4). a Basal respiration was determined, followed by sequential additions of oligomycin
(3 μM) to assess respiration due to proton leak, carbonyl cyanide 3-chlorophenylhydrazone (CCCP; 1.5 μM) to measure respiratory capacity,
rotenone (1 μM) to assess Complex I (CI) independent respiration and antimycin A (AMA; 1 μM) to determine background OCR. b Glucose
(10mM) was provided to determine basal glycolysis, followed by sequential additions of oligomycin (3mM) to obtain glycolytic capacity, CCCP
(1.5 μM) to evaluate the influence of uncoupling and 2-deoxyglucose (2-DG; 100mM) to measure the non-glycolytic background. c High-resolution
respirometry in H1_DL2 cells to detect direct effects of β-sitosterol. First, the maximal CI + CII driven respiratory capacity was measured in the presence
of digitonin (8.1 μM), malate (2mM), pyruvate (1mM), succinate (10mM) and carbonylcyanide-4-(trifluoromethoxy)-phenylhydraqone (FCCP, 0.18 μM).
The respiratory rate was then measured after adding β-sitosterol (50 μM) or DMSO (0.05%), followed by rotenone (0.5 μM) to inhibit CI, and AMA
(2.3 μM) to determine residual oxygen consumption. The experiment was repeated 3 times. a-c Student’s t-test: n.s. = not significant, P ≥ 0.05,
**** P < 0.0001. Values are given as the mean ± s.d
Fig. 6 β-sitosterol increases ROS production and apoptosis. a ROS content (CM-H2DCFDA probe; mean fluorescence intensity (MFI); n = 2 with
triplicates). b Flow cytometric apoptosis assay (n = 3) showing a strong induction of apoptosis following ß-sitosterol treatment. c Western blot of
pro-caspase-3, cleaved caspase-3 and GAPDH in H1_DL2 cells exposed to DMSO (0.05%) or β-sitosterol (50 μM) for 2, 24 or 24 h, respectively.
Student’s t-test: *** P < 0.001, **** P < 0.0001. Values are given as the mean ± s.e.m
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Intriguingly, we found the highest expression levels
for melanoma brain metastases (Additional file 13:
Figure S12a, b). There was no difference in NDUFB8
expression between BRAF mutated and BRAF wild
type melanoma brain metastases (Additional file 13:
Figure S12c). Taken together, our data suggest that
β-sitosterol prevents a key resistance mechanism to
BRAFi therapy and may therefore be a beneficial
therapeutic adjuvant in the treatment of melanoma
brain metastasis.
Discussion
In this study, we used computational predictions based
on gene expression analyses to identify potential drugs
against BRAF-mutant melanoma brain metastases. The
cholesterol analogue β-sitosterol was well tolerated,
effectively reduced the number and volume of brain
metastases, and improved survival in reproducible and
predictive human-to-mouse brain metastasis models. As
shown in Additional file 9: Figure S8, β-sitosterol may
assert its function on many biological processes. From a
Fig. 7 Mitochondrial complex I inhibition prevents BRAFi resistance. a. Western blot of PGC1α and GAPDH in H1 cells treated with DMSO (0.05%)
or β-sitosterol (12.5, 25 or 50 μM) for 24 h (n = 3). b. MitoTracker Red mean fluorescence intensity in H1 cells treated with DMSO (0.05%) or
vemurafenib (1.5 μM) for 72 h (n = 3). c Colony formation assay (crystal violet staining) of H1 cells treated with DMSO (0.05%) for 1 week, or
vemurafenib (1.5 μM), β-sitosterol (50 μM), or vemurafenib + β-sitosterol for 3 weeks (n = 3). d Western blot of NDUFA8 and β-actin in H1_shCtr
and H1_shNDUFA8 cells (NDUFA8 is required for assembly of a functional complex I). e Colony formation assay of H1 cells treated with DMSO
(0.05%) for one week or vemurafenib (1.5 μM) for three weeks, and H1_shNDUFA8 cells alone or treated with vemurafenib (1.5 μM) for three
weeks (n = 3). f Half maximal inhibitory concentration (IC50) values for β-sitosterol, PLX4720 and the combination thereof in Melmet 1, Melmet 5
and A375 cell lines (n = 3). g Subcutaneous tumor volume (width2 × length)/2) in mice injected with 1 × 106 Melmet 5 cells. Mice were from two
weeks onwards given daily i.p. injections of 0.1 mL vehicle (olive oil), 20 mg/kg β-sitosterol in olive oil, 25 mg/kg PLX4720 in 0.05% DMSO, or a
combination of the two latter (n = 8 in each group). Representative images of tumors at 44 days are shown in the right panel. Student’s t-test:
* P < 0.05. Values are given as the mean ± s.e.m
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therapeutic viewpoint, targeted therapies may have a
limited effect, based on their complexity (heterogeneity
and numerous cell signaling events occurring in me-
lanomas). In the current work, we have shown that
β-sitosterol has a particular effect on BRAF-driven
tumors, but this does not exclude an action of β-sitosterol
on other biological processes in tumor cells. For instance,
the PC14_PE6_Br2 lung adenocarcinoma cell line,
which is BRAF wild type, was also sensitive to
β-sitosterol treatment, but to a lesser extent. We found
in particular that the compound inhibited mitochon-
drial respiration through targeting of mitochondrial CI,
which is a major facilitator of intrinsic and acquired
resistance to MAPK-targeted therapies [24, 63]. Import-
antly, we also found that the combination of β-sitosterol
and a BRAFi exhibited a strong therapeutic effect, com-
pared to monotherapies.
Regarding a potential translational value of the pre-
sented findings, the preventive effect of β-sitosterol on the
establishment of brain metastasis should be highlighted
(Fig. 4). Since patients with melanomas and lung can-
cer show a significant propensity to develop brain
metastasis during disease progression, β-sitosterol
may, in a preventive setting, inhibit brain metastasis
from the primary tumor.
To our knowledge, this is the first example of successful
preclinical repurposing of a drug to treat melanoma-asso-
ciated brain metastases. Repurposing of approved,
non-anticancer drugs is an attractive drug discovery
strategy in cancer with substantial advantages of cheaper,
faster, and safer preclinical and clinical validation [11]. It
should also be emphasized that high doses (3–4 g) of
β-sitosterol can be given daily to patients without side
effects [30].
The phytosterol β-sitosterol is known as a competitive
inhibitor of intestinal cholesterol uptake [30]. Phytos-
terols are generally classified as safe by the United States
Food and Drug Administration, and the European Foods
Safety Authority has concluded that a daily phytosterol
and/or phytostanol intake of 1.5–2.4 g can reduce blood
cholesterol by 7–10.5% and sustain this effect for up to
85 weeks [13]. Notably, we used a daily dose of 5 mg/kg
in our experimental studies, which translates into 375
mg for a person weighing 75 kg. Randomized controlled
trials (RCTs) in humans have found beneficial effects of
β-sitosterol (and its ester) on hypercholesterolemia, but
also on benign prostatic hyperplasia, androgenic alope-
cia, and as an adjuvant in the treatment of tuberculosis,
and anogenital warts [9, 20, 35, 43, 53]. No clinical trials
have examined the effects of β-sitosterol on cancer.
However, epidemiological studies have suggested that
increased consumption of phytosterols can reduce the
risk of different cancers [19, 33, 38, 61]. Data from
cancer cell lines have shown that β-sitosterol can reduce
cell proliferation and induce apoptosis in addition to
inhibiting adhesion, invasion, and migration [2, 4–6, 8,
50, 64, 65, 70]. β-sitosterol has also been shown to in-
hibit the growth of tumor xenografts, reduce progression
of carcinogen-induced tumors, and prevent metastatic
lung and lymph node colonization [5, 8, 28, 29, 54]. The
anticancer effects of β-sitosterol remain somewhat elu-
sive, but a number of underlying mechanisms have been
proposed [23]. As a potential therapeutic agent against
brain metastases, it is particularly interesting that
β-sitosterol has been shown to cross the BBB and accu-
mulate in the brain [25, 62]. With respect to our findings,
it has previously been shown that β-sitosterol can in-
corporate into the inner mitochondrial membrane
where it increases membrane fluidity [47]. It is also
known that cancer cells may have an altered cholesterol
loading, that may impair mitochondrial function leading
to apoptosis protection [44]. Further studies on how
β-sitosterol causes metabolic alterations in cancer cells are
therefore warranted.
We found that, β-sitosterol displays broad-spectrum
effects at both the genomic, proteomic, and metabolo-
mic levels. Although extensive suppression of the MAPK
pathway appears to be particularly important for meta-
static melanoma, we also delineated a highly relevant
mechanism of β-sitosterol, namely the reduction of
mitochondrial respiration through CI inhibition with
concurrent induction of ROS leading to apoptosis. This
mitochondrial inhibition may have important rami-
fications for patients with metastatic melanoma, as
increased mitochondrial oxidative capacity has been
shown to mediate resistance to MAPK-targeted thera-
peutics and provide protection against oxidative damage
and apoptosis [24, 63, 68]. Previous studies have indi-
cated a therapeutic potential of various mitochondrial
inhibitors and CI inhibitors in melanoma [21, 24, 36, 45,
49, 63, 68, 69]. In BRAF-mutant melanoma brain me-
tastasis, we show that β-sitosterol efficiently prevented
resistance to BRAFi therapy in vivo. Furthermore, large-
scale analyses of human brain metastases indicated a
significant role of mitochondrial CI, which warrants
further investigation. Intriguingly, emerging evidence
suggests that mitochondrial respiration may be a par-
ticularly important survival mechanism and growth
facilitator for metastatic cells in the brain micro-
environment [7, 15, 16, 26].
Conclusions
In conclusion, we here leveraged robust in vivo model
systems of brain metastasis to demonstrate the effects of
β-sitosterol on BRAF-mutant melanoma [57]. Our study
also indicates a therapeutic potential beyond brain me-
tastasis that warrants further exploration in site-specific
model systems. Importantly, to accomplish translational
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advances in brain metastasis research, there is a strong
need for more preventive trials in selected high-risk
patients or in patients with limited brain involvement
[12]. Many metabolic modulators, including natural
compounds and drugs used for conditions other than
cancer, have favorable cost and toxicity profiles and
might offer additional therapeutic benefit in metastatic
melanoma. β-sitosterol can readily penetrate the BBB
and has been studied in several randomized clinical trials
of non-cancerous diseases [9, 20, 25, 35, 43, 53, 62].
Thus, our findings strongly encourage further assess-
ment of β-sitosterol as an adjuvant to established
MAPK-targeted therapies for patients with melanoma
brain metastases or patients at risk of developing
such metastases.
Additional files
Additional file 1: Figure S1. The diagram illustrates the step-by-step
workflow and analysis strategy used in the current study. (TIF 1390 kb)
Additional file 2: Figure S2. Generation of organ samples for RNA
sequencing, brain metastasis gene signature and Connectivity Map
analysis. a BLI five weeks after intracardiac injection of 5 × 105 H1_DL2
cells in NOD.CB17-Prkdcscid/NcrCrl mice (n = 7). M1-M7, indicate mouse 1
to 7. b Fluorescence-activated cell sorting (FACS) of GFP-positive tumor
cells from the metastatic lesions. The sorted cells were analyzed by RNA-
seq (n = 7). c Heatmap of the 108-gene brain metastasis signature with
organ samples in rows and genes in columns. d The brain metastasis
gene signature with the left two panels showing 54 upregulated genes
in brain metastases and the right two panels showing 54 downregulated
genes. e Query results from the Connectivity Map (cMap) database using
the 108-gene signature. A score of < 0 to − 1 means net reversal of the
signature (negative correlation) and a score of > 0 to + 1 means net
induction of the signature (positive correlation). (TIF 2033 kb)
Additional file 3: Table S1. Tissue Digestion Protocols. Preparation of
Liberase TM Research Grade (Roche Applied Science) working solution
and organ-tailored protocols for tissue digestion (brain, adrenals, ovaries
and bone). (DOCX 18 kb)
Additional file 4: Figure S3. Cell viability in vitro by increasing β-
sitosterol concentrations. Human melanoma cell lines: a Melmet 1, b
Melmet 5, and c A375 (n = 18 per cell line per drug per drug
concentration). Normal cells: d SV-80 human lung fibroblasts (n = 18 per
drug concentration), e hTERT immortalized melanocytes and f Human
astrocytes. All values are given as the mean ± s.e.m. (TIF 943 kb)
Additional file 5: Figure S4. In vivo efficacy of candidate compounds
on H1_DL2 brain metastases. a Left panel: Tumor cell load into the brain
was quantified by MRI-based automated quantification of nanoparticle-
labeled cells in NOD/SCID mouse brains 24 h after intracardiac injection
of 5 × 105 H1_DL2 cells. Right panel: Images show typical MRI T2*-
weighted images of mouse brains (scale bar, 0.25 cm) with an overlay of
detected signals (blue). Study groups received 0.2 mL i.p. injections of 40
mg/kg thiostrepton every second day (n = 5), 10 mg/kg memantine daily
(n = 5), 5 mg/kg β-sitosterol daily (n = 4) or vehicle (0.5% DMSO; n = 5)
from one week post-injection. See Fig. 3 for more details on this
experiment. b Volume of brain metastases determined by MRI (T1-
weighted with contrast). Total volume of brain metastases per animal
was compared at group level. c Brain BLI (total photon count = dorsal
+ ventral region of interest (ROI). a-c Student’s t-test: n.s. P ≥ 0.05, *
P < 0.05, ** P < 0.01, *** P < 0.001. All values are given as the mean ±
s.e.m. (TIF 3422 kb)
Additional file 6: Figure S5. In vivo validation of β-sitosterol on
H1_DL2 brain metastasis. a Initial tumor cell load into the brain assessed
by MRI-based automated quantification of nanoparticle-labeled cells 24 h
after intracardiac injection of 5 × 105 H1_DL2 cells. Images show typical
MRI T2*-weighted images of mouse brains (scale bar, 0.25 cm) with an
overlay of detected signals (blue). The study groups received daily i.p.
injections of 0.1 mL vehicle (olive oil; n = 10) or β-sitosterol 5 mg/kg
diluted in olive oil (n = 9) starting one week before tumor cell injections.
See Fig. 4 for more details on this experiment. b Body weight from week
zero to eight. At 100 days, the three remaining β-sitosterol mice had an
average body weight of 26.7 ± 0.6 g. c Volume of brain metastases
assessed by MRI (T1-weighted with contrast). Total volumes of brain me-
tastases per animal were compared at group level. a-c Student’s t-test:
n.s. P ≥ 0.05, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. All values
are given as the mean ± s.e.m. (TIF 726 kb)
Additional file 7: Figure S6. β-sitosterol treatment effect is not model
specific. a Experiment overview. Mice were injected intracardially with
5 × 105 PC14_PE6_Br2 cells. Test groups received daily i.p. injections of
0.1 mL vehicle (olive oil; n = 4) or β-sitosterol 5 mg/kg (n = 6). Treatment
started one week prior to tumor cell injections and was continued until
euthanization. b Body weight from week zero to four for vehicle and β-
sitosterol-treated mice. c Number and d volume of brain metastases at
MRI at three weeks (T1-weighted with contrast). Total volume of brain
metastases per animal compared at group level. e Brain BLI at three
weeks (total photon count = dorsal + ventral region of interest). b-e
Student’s t-test: n.s. P ≥ 0.05, * P < 0.05, ** P < 0.01, *** P < 0.001. f
Kaplan-Meier survival plot (Mantel-Cox log-rank test: *** P < 0.001). All
values are given as the mean ± s.e.m. (TIFF 2165 kb)
Additional file 8: Figure S7. a Functional classification of the brain
metastasis gene signature. Human biological processes (metabolic
processes are highlighted in red), and b signaling pathways associated
with the 108-gene brain metastasis signature using the Protein Analysis
Through Evolutionary Relationships (PANTHER) classification system. c
Known and predicted protein interactions of β-sitosterol from the Search
Tool for Interactions of Chemicals (STITCH 4.0). Green lines represent
direct interactions with β-sitosterol whereas blue lines represent protein-
protein interactions. Direct activation (green arrows) or inhibition (red
lines) is indicated. d Significant statistical associations of β-sitosterol
targets with cellular processes predicted with the Human Experimental/
Functional Mapper (HEFalMp). P-values represent approximate multiple
hypothesis corrected values. (TIF 1333 kb)
Additional file 9: Figure S8. Protein phosphorylation screening
following β-sitosterol treatment. Parallel determination of protein
phosphorylation levels (43 oncogenic kinases and two total proteins) in
H1_DL2 cells after 24 h treatment with vehicle (0.05% DMSO) or β-sitosterol
(50 μM). (TIF 418 kb)
Additional file 10: Figure S9. Interaction network of signature genes
and oxidative phosphorylation. The 121 Gene Ontology (GO)-annotated
genes implicated in oxidative phosphorylation (red nodes) have 163
experimentally validated protein-protein and protein-DNA interactions
involving 143 genes/proteins, including eight signature genes (green
nodes). Purple nodes: Other genes that mediate interactions between
signature and oxidative phosphorylation genes. Interaction directionality
is represented with arrows. (TIF 1057 kb)
Additional file 11: Figure S10. Interaction network of β-sitosterol targets
and oxidative phosphorylation. The 121 Gene Ontology (GO)-annotated
genes implicated in oxidative phosphorylation (red nodes) have 155 experi-
mentally validated protein-protein and protein-DNA interactions involving
141 genes/proteins, including four β-sitosterol targets (green nodes). Purple
nodes: Other genes that mediate interactions between β-sitosterol targets
and oxidative phosphorylation genes. Interaction directionality is
represented with arrows. (TIF 1056 kb)
Additional file 12: Figure S11. The respiratory capacity (OCR) in normal
melanocytes following β-sitosterol treatment as measured by the
Seahorse system. Compared to the tumor cells (Fig. 5a) no changes in
respiratory capacity was observed. (TIF 263 kb)
Additional file 13: Figure S12. Mitochondrial complex I activity in
human brain metastases. a Expression levels of complex I subunit
NDUFB8 in 197 human brain metastases from different cancers:
Carcinoma not otherwise specified (NOS; n = 9), colon cancer (n = 9),
breast cancer (n = 25), renal cell cancer (RCC; n = 9), non-small cell lung
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cancer (NSCLC; n= 52), small cell lung cancer (SCLC; n= 7), melanoma (n= 78)
and others (n = 8). H-Score = [staining intensity (1 = weak, 2 = moderate,
3 = strong)] x [frequency of positive cells (%)]. Kruskal-Wallis test with
Dunn’s multiple comparisons test: * P < 0.05, ** P < 0.01, **** P < 0.0001
and for comparisons not indicated P ≥ 0.05. b Immunohistochemistry of
NDUFB8 in a human melanoma brain metastasis. c Expression levels of
complex I subunit NDUFB8 in BRAF mutated melanoma (BRAFV600E; n = 24)
and BRAF wild type melanoma (no BRAFV600E; n = 23). Kruskal-Wallis test
with Dunn’s multiple comparisons test: n.s.: not significant. (TIFF 12141 kb)
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